I believe that any peer reviewers will clearly understand what's happening, any attempt to snow them will only result in delays. No doubt when you create K-M plots for every possibility some will be better than others. If any are clearly not an improvement on the SOC they won't be included in the label for the vaccine.
The thing is, once approved it can be used off label, and it may very well be true that the vaccine can be more effective when used with different therapeutics than were used in the trial. UCLA is clearly trying other combinations with the vaccine, I have little doubt that they'll find new combinations that improve on the results of the trial in many of the different forms of GBM.
The good news is our vaccine isn't doing what so many other approved products do, I.E. increasing the life span of patients by 10%, 20% or more. Our vaccine is multiplying the length of time people live, and may be curing some of them. Dr. Liau has clearly said that by itself it's not the answer, but in combination with other therapeutics, some which don't yet exist, it should be. I suspect the same will be found when it's tried with other solid cancers, by itself it's not the answer, but improvements will occur when it's added to the current therapeutics, and future therapeutics will make it even better.
Gary
News 
Market Data 
Discover 
AI
